Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

J & J to Pay $181M under Risperdal Settlement

By Pharmaceutical Processing | August 31, 2012

Johnson & Johnson’s Janssen Pharmaceuticals unit on Thursday announced that it will pay approximately $181 million under a settlement and consent decree with 36 U.S. states and the District of Columbia regarding previously disclosed allegations that it improperly promoted and marketed Risperdal (risperidone). Janssen reaffirmed as part of the settlement that it would not promote any of its atypical antipsychotics for off-label uses or make any false or misleading claims related to those products.

The drugmaker noted that the settlement is not an admission of wrongdoing or violation of any law or regulation and that all parties agreed the payment is not considered a fine or penalty. Janssen president Michael Yang commented that “we have chosen this path to achieve a prompt and full resolution of these state claims.” The company added that it “takes its obligation to ensure the safe and appropriate use of its medications very seriously” and has a system in place to ensure that its marketing policies are followed. Florida Attorney General Pam Bondi said the agreement “sends a message to all pharmaceutical companies that these practices will not be tolerated.”

In July, sources suggested that Johnson & Johnson agreed to pay as much as $2.2 billion to resolve claims made by the US government and some states regarding the marketing of Risperdal and other drugs, including a criminal fine of as much as $600 million for the illegal promotion of Risperdal. The sources noted at the time that the final sum of the payout would depend on which states agreed to the settlement.

Johnson & Johnson noted that today’s settlement is separate from the agreement in principle reached with the U.S. Department of Justice earlier this month to settle three civil False Claims Act matters that are pending in U.S. court regarding the sales and marketing of Risperdal, Invega (paliperidone) and Natrecor (nesiritide), as well as allegations that Omnicare was provided with rebates and other payments regarding several products.

 

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE